MDxHealth SA (NASDAQ:MDXH) Sees Significant Increase in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 39,057 shares, an increase of 129.3% from the February 26th total of 17,033 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 99,293 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of MDxHealth

Several hedge funds have recently made changes to their positions in the business. Intesa Sanpaolo Wealth Management bought a new position in shares of MDxHealth in the 4th quarter valued at about $36,000. GSA Capital Partners LLP bought a new stake in MDxHealth during the third quarter worth approximately $48,000. Lido Advisors LLC bought a new stake in MDxHealth during the third quarter worth approximately $48,000. Citadel Advisors LLC raised its position in MDxHealth by 30.6% during the third quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock valued at $228,000 after purchasing an additional 11,456 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new stake in MDxHealth during the third quarter valued at approximately $53,000.

Analyst Ratings Changes

MDXH has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating and set a $7.00 target price on shares of MDxHealth in a research note on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

MDxHealth Price Performance

Shares of NASDAQ MDXH traded down $0.16 during midday trading on Thursday, reaching $2.70. 148,300 shares of the stock traded hands, compared to its average volume of 139,366. The company’s 50 day moving average is $3.48 and its 200 day moving average is $3.76. MDxHealth has a one year low of $1.36 and a one year high of $5.33. The stock has a market capitalization of $133.65 million, a PE ratio of -4.03 and a beta of 1.61.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). The business had revenue of $29.55 million during the quarter, compared to the consensus estimate of $26.05 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%. As a group, equities analysts forecast that MDxHealth will post -1.15 EPS for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.